HOLX News and Press, Hologic Inc. From 02/17/23

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The appellate court ruled that Minerva’s patent is invalid because it waited mor...

Hologic ( NASDAQ: HOLX ) said its V5 global endometrial ablation designed to treat a wide range of cervical and uterine anatomies had been approved in Canada and Europe. NovaSure V5 has a cervical seal, featuring EndoForm technology, designed to increase the sealing sur...

Hologic Inc. (Nasdaq: HOLX), a global leader in women's health, has announced approval of the NovaSure ® V5 global endometrial ablation (GEA) device in Canada and Europe. This innovative new version incorporates enhanced features designed to treat a wide range of cervical and uterine ana...

Hologic, Inc. (HOLX) Q1 2023 Earnings Conference Call February 1, 2023 04:30 PM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Jack M...

The following slide deck was published by Hologic, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Hologic, Inc. 2023 Q1 - Results - Earnings Call Presentation

Hologic press release ( NASDAQ: HOLX ): Q1 Non-GAAP EPS of $1.07 beats by $0.14 . Revenue of $1.07B (-27.2% Y/Y) beats by $60M . Diagnostics revenue decreased (41.2%), or (39.4%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the p...

– Revenue of $1,074 Million, GAAP Diluted EPS of $0.75, and Non-GAAP Diluted EPS of $1.07 All Exceed Guidance – – Broad-Based Organic Revenue Growth ex. COVID-19; Diagnostics and Surgical Grow Double-Digits in Constant Currency – – Company Increases Full...

Summary InMode Ltd. has 80%+ gross margins and 40%+ operating margins within a growing industry. The market is overestimating short-term worries that likely won't have a material effect on long-term cash flows. On both a relative basis and through a discounted cash flow, I estimate ...

Summary Hologic was a beneficiary of the pandemic, catching a strong bid across that period. With its FY22 numbers, investors have re-rated the stock back to the upside. We believe a further re-rating is warranted, and that the stock deserves a high P/E based on its return on capita...